A year after missing on a trial endpoint, Travere Therapeutics can breathe a sigh a relief. | A year after missing on a trial ...

On Thursday, the FDA granted accelerated approval to Novartis AG’s (NYSE ... at risk of rapid disease progression. In ...

Novartis said it received accelerated approval from the U.S. Food and Drug Administration for a treatment to bring down elevated levels of protein in the urine of adults who have a rare kidney ...

London: The U.S. Food and Drug Administration has approved the use of Novartis' drug to reduce excess protein in the urine of patients with a type of kidney disease ... The FDA's latest approval ...

The company had focused its resources on Filspari’s launch in IgAN after the US FDA snubbed the therapy in another rare ...

Looking to build on the success of Chinook Therapeutics, founded by Versant in 2019 and acquired by Novartis last year, the ...

The FDA says the latest vaccine formulae "closely targets currently circulating variants" to give better protection against ...

A medication that is commonly used for chronic kidney disease has been found to reduce the risk of worsening heart failure ...

A chemist a UAlbany and his son are looking to make a major breakthrough in the world of Alzheimer's prevention. They believe ...